PFO
KYNB

Pathstone Family Office’s Kyntra Bio KYNB Stock Holding History

Pathstone Family Office’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Hold
0
– – – 899
2020
Q4 		– Hold
0
– – – 1204
2020
Q3 		– Hold
0
– – – 865
2020
Q2 		– Sell
-2
Closed -$1.86K – 805
2020
Q1 		$2K Buy
+2
New +$1.99K ﹤0.01% 687
2019
Q2 		– Sell
-3
Closed -$3K – 719
2019
Q1 		$3K Hold
3
– – ﹤0.01% 682
2018
Q4 		$3K Buy
+3
New +$3.37K ﹤0.01% 420

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pathstone Family Office's KYNB Position: Q1 2021 in Review

Pathstone Family Office held its Kyntra Bio (KYNB) position steady in Q1 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Pathstone Family Office first reported a position in KYNB in Q4 2018 and has held it in 3 quarters since. The position peaked at $3K in Q1 2019. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

  • Pathstone Family Office held 0 shares of Kyntra Bio worth $0 as of Q1 2021.
  • Pathstone Family Office left its Kyntra Bio share count unchanged in Q1 2021.
  • Kyntra Bio made up ﹤0.01% of Pathstone Family Office's portfolio in Q1 2021, its #899 holding.
  • Pathstone Family Office first reported a position in Kyntra Bio in Q4 2018 and has held it in 3 quarters since.
  • Pathstone Family Office's Kyntra Bio position peaked at $3K in Q1 2019.
  • 198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.